Recent Changes — Food, Drug & Device

The federal-food-drug-device-controlled-substances statutory foundation: Federal Food, Drug, and Cosmetic Act of 1938 (FFDCA; 21 U.S.C. § 301 et seq.) — Chapter IV foods (21 U.S.C. §§ 341-350l), Chapter V drugs and devices (21 U.S.C. §§ 351-360fff), Chapter IX tobacco (21 U.S.C. § 387 et seq.; added by 2009 TCA). Federal Meat Inspection Act (FMIA; 21 U.S.C. § 601 et seq.; foundational 1906 with 1967 amendments). Poultry Products Inspection Act (PPIA; 21 U.S.C. § 451 et seq.; 1957). Egg Products Inspection Act (EPIA; 21 U.S.C. § 1031 et seq.). Controlled Substances Act of 1970 (CSA; 21 U.S.C. § 801 et seq.) — Schedule I-V framework; DEA registration; quotas; suspicious-order monitoring. Statutory layer composite: HIGH stability — federal statutes themselves are not eroding; the foundational architecture remains; agency-layer and rule-availability layers are where 2025-2026 erosion is documented.

Affects: all seven sub-domains. Sources: FFDCA at 21 U.S.C.; FMIA + PPIA + EPIA at 21 U.S.C. §§ 601 / 451 / 1031; CSA at 21 U.S.C. § 801 et seq.

The Family Smoking Prevention and Tobacco Control Act of 2009 (FSPTCA / TCA; Pub. L. 111-31; 21 U.S.C. § 387 et seq.) established FDA tobacco regulatory authority — PMTA framework; modified-risk tobacco; flavor restrictions; minimum age federalized as Tobacco 21 in 2019. Bipartisan 2009 enactment; statutory stability HIGH. The TCA grounds the FDA Center for Tobacco Products (CTP) at Silver Spring, MD with field activities through FDA OII Philadelphia District. The menthol cigarette ban proposed rulemaking originated in 2022 under TCA authority; the January 21, 2025 withdrawal operates within the TCA framework without altering the statutory authority itself.

Affects: Tobacco (principal anchor at SD5). Sources: FSPTCA at Pub. L. 111-31; 21 U.S.C. § 387 et seq.

The Food Safety Modernization Act of 2011 (FSMA; Pub. L. 111-353; 21 U.S.C. § 350g et seq.) established Preventive Controls, Produce Safety, FSVP, and intentional-adulteration rules — statutory stability HIGH; bipartisan implementation through 2022 final rules. FSMA operates as the central federal food-safety architecture under FDA HFP/OII (post-July 1, 2024 reorganization) — Philadelphia District at Mellon Independence Center. The April 2025 FDA RIF (per [MC-07](https://github.com/square-party/square-party-site/blob/main/reference-info/verified-pa3-domain-content/D4-food-drug/D4_foodMed_verified_2026-04-29.md#mc-07)) and HFP/OII reorganization implementation status operate within the FSMA framework without altering the statutory authority itself.

Affects: Food (principal anchor at SD1). Sources: FSMA at Pub. L. 111-353; 21 U.S.C. § 350g et seq.

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA; 21 U.S.C. § 364 et seq.) requires facility registration, product listing, safety substantiation, adverse-event reporting, and recall authority — phased implementation through 2026-2028. MoCRA implementation lag through 2026-2028 leaves the federal cosmetics modernization tool incompletely operative during the implementation window when remediation for hair-product chemical exposure for Black PA-3 women would be operationally available. XC-11 application — small / Black-owned cosmetics manufacturers under MoCRA exemption thresholds may serve PA-3 Black women cosmetics consumers more directly than conglomerated-brand products do; whether the small-business exemption thresholds reach these manufacturers is structurally consequential to remediation reach (F4-T2P2-SD1-MoCRA-1 verification pending).

Affects: Food (principal anchor at SD1). Sources: MoCRA at 21 U.S.C. § 364 et seq.; FDA cosmetics implementation guidance.

Menthol cigarette ban (RIN 0910-AI60) and characterizing-flavors-in-cigars rule (RIN 0910-AI28) withdrawn January 21, 2025 — Trump's second day in office. Withdrawals removed from OMB regulatory agenda. Pending litigation: AATCLC v. HHS in Northern District of California; February 4, 2025 status conference — both sides agreed withdrawal "neither terminates nor publishes the regulation." Public Health Law Center / African American Tobacco Control Leadership Council 2013 Citizen Petition still pending. Menthol = 35% of US cigarette sales; ~85% of Black smokers use menthol. NPRM 2022 preamble disparate-impact citations remain available for primary-source retrieval (F4-T2P2-SD5-2). Nicotine reduction NPRM remains open for comments until September 15, 2025 (status post-CTP RIF: pending). The federal regulatory architecture acknowledged the disparate-impact pattern in its own regulatory preamble, developed the substantive remediation tool, withdrew the tool, and then decimated the regulatory-development capacity through the April 2025 CTP Office of Regulations RIF (per [MC-07](https://github.com/square-party/square-party-site/blob/main/reference-info/verified-pa3-domain-content/D4-food-drug/D4_foodMed_verified_2026-04-29.md#mc-07)) — the foreclosed-remediation pattern.

Affects: Tobacco (principal anchor at SD5). Sources: RIN 0910-AI60 + RIN 0910-AI28 OMB unified agenda; AATCLC v. HHS N.D. Cal.; Public Health Law Center 2013 Citizen Petition.

The LDT (Laboratory Developed Tests) framework FDA 2024 final rule was vacated by federal court on March 31, 2025 — regulatory status VACATED; LOW post-vacatur. The vacatur leaves algorithmic clinical decision-support tools operating under CLIA-only oversight without federal premarket validation. Documented racial-pattern bias instances in clinical algorithms persist in the broader literature without federal remediation pathway. CDRH capacity erosion per [MC-07](https://github.com/square-party/square-party-site/blob/main/reference-info/verified-pa3-domain-content/D4-food-drug/D4_foodMed_verified_2026-04-29.md#mc-07) (~260 fired including 40 from Digital Health Center of Excellence; Office of Women's Health "rendered effectively non-functional") compounds the operational gap precisely where the algorithmic decision-support remediation infrastructure would be developed.

Affects: Biologics & Devices (principal anchor at SD4). Sources: federal court vacatur March 31, 2025; FDA LDT framework 2024 final rule.

April 1, 2025 FDA RIF affected ~3,500 personnel = 19% of workforce. HHS announcement March 27, 2025; RIF effective April 1, 2025. Per-Center detail: CDER lost ~1,000 employees over three months (between RIFs, voluntary retirements, probationary firings); FY2025 CDER lost 473 employees vs 120 hired; FY2025 Q2-Q3 CDER lost 385 vs 18 hired. CDRH ~260 fired, including 40 from Digital Health Center of Excellence. Office-level decimation: CDER's Office of Medical Policy + CBER's Office of Regulatory Operations + CDRH Office of Women's Health + Division of Policy Development within Office of Generic Drug Policy "rendered effectively non-functional." Leadership departures: CBER Director Peter Marks departed; CDER Office of New Drugs head Peter Stein resigned as part of RIF; CBER Acting Director Julie Tierney + Associate Director for Policy James Myers + Director of Regulatory Operations Chris Joneckis terminated; CDER top leaders Patrick Raulerson + Carter Beach affected. CTP Director Brian King removed April 1, 2025; Bret Koplow appointed Acting Director. HHS finalized RIF July 14, 2025 (after Supreme Court stayed CA injunction). Rhode Island injunction: Per Venable LLP, CTP RIF, CDC, Office of Head Start, and Office of the Assistant Secretary for Planning and Evaluation subject to Rhode Island injunction as of July 2025.

Affects: SD1 + SD3 + SD4 + SD5 federal capacity erosion; SD7 §10 TCT (principal federal-cluster anchor). Sources: HHS announcement March 27, 2025; AP reporting; Venable LLP July 2025 client alert; Stat News + Bloomberg Law per-Center reporting.

April 2025 USDA workforce reductions affected 11,300+ deferred resignations effective; FSIS Philadelphia District 60 (Mellon Independence Center, 900 US Customhouse, 2nd & Chestnut, Philadelphia, PA 19106) staffing actuals reduced (F4-T2P2-SD2-2 staffing pending direct retrieval). PA non-cooperative MPI status concentrates federal-FSIS demand on FSIS Philadelphia District 60 at the precise moment when the federal capacity at District 60 is reduced through the April 2025 USDA workforce reductions. New FSIS leadership: Dr. Hany Sidrak = FSIS Chief Public Health Veterinarian; Dr. Mindy Brashears sworn as Under Secretary January 14, 2026; USDA Secretary Brooke Rollins attended the January 14, 2026 Salmonella public meeting.

Affects: Meat & Poultry (principal anchor at SD2). Sources: USDA workforce announcement April 2025; FSIS Philadelphia District 60.

April 25, 2025 Salmonella Framework for Raw Poultry Products withdrawal (90 FR 17344) confirmed. December 2025: FSIS indefinitely delayed sampling and verification activities for the April 2024 finalized determination declaring Salmonella an adulterant in NRTE (not-ready-to-eat) breaded and stuffed chicken products at >1 CFU/g; FSIS cited "limitations in available test methods" — disputed by Consumer Reports' Dr. Michael Hansen who notes FSIS's own qPCR method (bioMérieux GENE-UP QUANT) is validated for 1 CFU/g. January 14, 2026 public meeting (Docket No. FSIS-2025-0179): USDA Secretary Brooke Rollins + new Under Secretary Dr. Mindy Brashears (sworn same day) attended; comment period extended to March 4, 2026. Cheaper-cut Salmonella exposure pathway quantified: Salmonella detection 4.14% chicken carcasses / 7.62% chicken parts / 24.2% comminuted chicken (2022 data) — supporting cheaper-cut consumer exposure concentrated in lower-income predominantly Black PA-3 consumer households post-Framework withdrawal.

Affects: Meat & Poultry (principal anchor at SD2). Sources: 90 FR 17344; Docket FSIS-2025-0179 (January 14, 2026 public meeting); Consumer Reports Dr. Michael Hansen response.

June 2025 ACIP overhaul: RFK Jr. removal of all 17 ACIP members; new appointees. October/November 2025 vaccine removals. January 5, 2026 schedule overhaul (17 → 11 diseases — corrected from earlier reporting). March 16, 2026 U.S. District Judge Brian E. Murphy (D. Mass.) ruling — plaintiffs AAP, IDSA, APHA, ACP, Society for Maternal-Fetal Medicine, Massachusetts pediatric chapters, three Jane Doe individuals — found ACIP appointments violated Federal Advisory Committee Act; halted 13 new ACIP appointments + all post-June 2025 votes (including hep B newborn vote, COVID downgrade) + government memo enacting new schedule. Court did NOT block earlier order on COVID vaccines for healthy children + pregnant individuals. April 9, 2026 — HHS rewrote ACIP charter broadening scope to include "novel vaccine platforms such as mRNA vaccines" and reviewing schedules of other countries; HHS spokesperson Andrew Nixon framed it as "routine statutory requirements." August 2025: HHS canceled ~$500M in federal mRNA research funding.

Affects: Biologics & Devices (principal anchor at SD4). Sources: U.S. District Court D. Mass. (Judge Brian E. Murphy); HHS April 9, 2026 charter rewrite; AAP / IDSA / APHA / ACP plaintiff filings.

First-round 10 drugs effective January 1, 2026 (38-79% off list); November 25, 2025 — CMS announced negotiated MFPs for Round 2 (15 drugs; 38-84% discounts; effective January 1, 2027); estimated $12B annual Part D savings + $685M OOP savings. OBBBA P.L. 119-21 (signed July 4, 2025) broadened orphan-drug exclusion under IRA (drugs designated for multiple rare diseases now excluded; affects drugs like Keytruda); CBO estimates +$8.8B Medicare spending = ~10% reduction in IRA program savings (from $98.5B to ~$89.7B). GENEROUS Model — voluntary Medicaid 5-year MFN-pricing model launched January 1, 2026 (through December 31, 2030; UK/France/Germany/Italy/Canada/Japan/Denmark/Switzerland reference). Trump EO 14273 implementation ahead of schedule per Applied Policy August 2025 reporting. Per ASPE: only 11% of non-LIS Part D enrollees in coinsurance plans will spend less per prescription due to MFP. The defining D4 SD3 paradox: IRA's pricing protection arrives operative simultaneous with PA-3 physical pharmacy access architecture collapse (Rite Aid closures August 22-24, 2025; ~80+ PA pharmacies closed since January 2024; ~20% PA pharmacy reduction; SVI 30-40% closure correlation).

Affects: Drugs (CDER + CVM + IRA pricing) (principal anchor at SD3). Sources: CMS IRA MFP publications; OBBBA P.L. 119-21; CBO orphan-drug analysis; ASPE Part D coinsurance analysis; Applied Policy August 2025 reporting.

All Rite Aid PA pharmacies closed by August 22, 2025 (PA-wide); final Philadelphia stores closed August 24, 2025; ~80+ PA pharmacies closed since January 2024; ~20% PA pharmacy reduction; SVI 30-40% closure correlation indicating disproportionate impact in compound-disadvantage tracts. Documented PA-3 sub-area Rite Aid closures: 9th Street/Italian Market (S. Phila); Grays Ferry (S. Phila/SW Phila); Aramingo Avenue (Northwest); Eastwick (SW Phila); Woodland Avenue (SW Phila) — 4 of 5 documented PA-3 closures concentrated in South/Southwest Philadelphia. PA Act 77 of 2024 PBM reform (staggered implementation pending) addresses PBM reimbursement architecture pressure at state layer — independent pharmacies as load-bearing XC-11 case at SD3.

Affects: Drugs (principal anchor at SD3); cross-cuts SD4 vaccine administration, SD5 cessation pharmacotherapy, SD6 buprenorphine availability. Sources: Rite Aid PA-wide closure documentation August 2025; PA Department of State Board of Pharmacy data; SVI demographic analysis.

Termination announced September 20, 2025; framed as "redundant, costly, politicized, and extraneous." Final report ERR-358 (Rabbitt et al. 2025) published December 2025 — delayed from October 2025 due to 43-day government shutdown. Verified rates from final report: 13.7% household FI in 2024 (statistically unchanged 2022-2024); Black households 24.4% / Latinx 20.2% / White 10.1% food insecurity 2024; 14.1 million children in food-insecure households; 36.8% single-parent female-headed households (up from 34.7% 2023); 47.4 million people affected. ERS budget = $310.5M = 0.2% of USDA budget — challenging USDA's "costly" rationale per Union of Concerned Scientists analysis. OBBBA H.R. 1 cut $186 billion from SNAP (separate from ERS termination but compounding the data-infrastructure + benefit gap). What the federal government can no longer see, the federal regulatory architecture can no longer respond to.

Affects: Food (principal anchor at SD1); SD7 data-infrastructure rollback. Sources: USDA ERS termination announcement September 20, 2025; ERR-358 (Rabbitt et al. 2025); Union of Concerned Scientists analysis; OBBBA P.L. 119-21.

Casgevy + Lyfgenia FDA-approved December 8, 2023; Casgevy $2.2M list; Lyfgenia $3.1M list. Vertex/CRISPR FY2025 earnings (February 2026): Casgevy globally infused 64 patients in 2025 (30 in Q4 alone); 147 first cell collections in 2025 (nearly 3× 2024); cumulative ~165 first cell collections since launch; ~300 patients referred to ATCs; Casgevy 2025 revenue $116M; FY26 guidance $500M (with Journavx). ~90% of US patients have reimbursed access per Vertex. Vertex received Commissioner's National Priority Review Voucher (CNPV) for Casgevy. Lyfgenia ~100+ patients treated since launch (Genetix Bio executives); bluebird bio sold for $30M in 2025 amid financial difficulties; rebranded as Genetix Biotherapeutics. Provider education cited as significant barrier ("doctors are discouraging patients"). Total US uptake ~164 cumulative through 2025 — substantially confirms low-uptake framing; Philadelphia paradox structural barriers documented at national level, not Philadelphia-specific. Both/And designation: substantive cell-and-gene-therapy availability AND Philadelphia paradox low uptake.

Affects: Biologics & Devices (principal anchor at SD4). Sources: Vertex Pharmaceuticals FY2025 earnings February 2026; Genetix Biotherapeutics (formerly bluebird bio); FDA CNPV designation.

DEA Final Order effective April 28, 2026 (Federal Register publication; FR Doc. 2026-08176; Vol. 91 No. 81), pursuant to Trump EO 14370 (Increasing Medical Marijuana and Cannabidiol Research; December 18, 2025). DOJ Final Order issued April 23, 2026 (Acting Attorney General; Order No. 6753-2026). DEA Medical Marijuana Dispensary Registration Portal opens April 29, 2026 at 9:00 AM EST with $794 annual application fee (initially payable via PayPal only); 60-day priority window through ~June 27, 2026. Adult-use cannabis remains Schedule I; only FDA-approved products + state-licensed medical cannabis rescheduled; synthetically derived THC (delta-10) excluded. New DEA hearing on broader rescheduling: June 29 - July 15, 2026 (recess July 3, reconvene July 6). Section 280E deduction disallowance lifted effective immediately for state-licensed medical cannabis; DOJ Final Order encouraged Treasury to consider "retrospective relief" from 280E for prior tax years. Prior NPRM (89 FR 70148) and hearing withdrawn April 22, 2026 (FR Doc. 2026-08178). SD6 is the only D4 sub-domain documenting federal architecture expansion rather than withdrawal.

Affects: Controlled Substances (principal anchor at SD6). Sources: FR Doc. 2026-08176 (Vol. 91 No. 81); Trump EO 14370; DOJ Final Order No. 6753-2026; FR Doc. 2026-08178 (prior NPRM withdrawal).